重新思考剂量测定:欧洲视角
文章从欧洲视角审视放射性药物治疗(RPT)剂量测定的现状,指出尽管分子影像与临床证据推动个体化治疗,但剂量测定在临床实践中实施仍有限,部分源于缺乏常规剂量测定限制临床证据、进而阻碍其推广的自我强化循环。文章讨论剂量驱动治疗计划与治疗后吸收剂量验证的区别,强调后者作为临床采纳的实用切入点,并呼吁统一标准、改善影像分辨率及建立反映RPT异质性的吸收剂量-效应关系。
要点
- RPT正进入个体化新时代,吸收剂量与治疗结局的临床证据不断增加。
- 剂量测定临床应用有限,部分源于缺乏常规剂量测定限制临床证据的自我强化循环。
- 治疗后吸收剂量验证被强调为临床采纳剂量测定的实用切入点。
核心结论
- 打破缺乏常规剂量测定限制临床证据、进而阻碍其推广的自我强化循环,对推进RPT至关重要,应基于临床价值而非后勤限制来评估剂量测定。
- 通过重新思考剂量测定并推广标准化、循证的方法,该领域可从固定活度方案迈向真正的个体化RPT。
- 实现剂量测定与常规实践在临床上可行的整合,需要有结构化的努力来生成高质量临床证据并改善可及性。
研究设计与样本
- 本文为欧洲视角的论述性文章,旨在促进关于RPT剂量测定的更事实性和建设性讨论。
主要发现
- 外照射放疗早已将剂量测定纳入标准实践,而RPT历史上依赖固定放射性药物活度及改编自外照射放疗的吸收剂量-效应关系,常未考虑全身给药放射性药物的独特药代动力学、吸收剂量率动态和生物学反应。
- 随着RPT扩展到更早期疾病阶段,患者预期寿命更长、体能状态更好,剂量测定在优化治疗中的作用日益明显。
- 文章强调需要统一标准、改善影像分辨率,以及建立反映RPT给药异质性和肿瘤与器官反应复杂性的定制吸收剂量-效应关系。
- 文章还讨论了RPT剂量测定实施的监管、基础设施和资源障碍,并介绍欧洲正在进行的加强框架、促进利益相关方协作及将吸收剂量生物标志物整合入授权流程和临床决策的举措。
临床怎么用
- 文章强调治疗后吸收剂量验证作为临床采纳剂量测定的实用切入点。
- 文章指出需要通过结构化努力生成高质量临床证据并改善可及性,以实现剂量测定与常规实践在临床上可行的整合。
局限性
- 文章指出剂量测定在临床实践中的实施仍然有限,部分原因是缺乏常规剂量测定限制临床证据、进而阻碍其更广泛采纳的自我强化循环。
- 文章指出实现剂量测定与常规实践在临床上可行的整合,需要有结构化的努力来生成高质量临床证据并改善可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical therapy (RPT) is entering a new era of personalization, driven by advances in molecular imaging, radiopharmaceutical development, and a growing body of clinical evidence linking absorbed dose to treatment outcomes. Although external-beam radiotherapy has long integrated dosimetry into standard practice, RPT historically relied on fixed radiopharmaceutical activities and absorbed dose-effect relationships adapted from external-beam radiotherapy, often without accounting for the unique pharmacokinetics, absorbed dose rate dynamics, and biologic responses of systemically administered radiopharmaceuticals. As RPT expands into earlier disease stages, at which patients have longer life expectancies and better performance status, the role of dosimetry in optimizing treatment is becoming increasingly evident. However, despite growing recognition of its benefits, the implementation of dosimetry in clinical practice remains limited, partly because of a self-reinforcing cycle in which the lack of routine dosimetry limits clinical evidence, which in turn hinders its broader adoption. Breaking this cycle is essential to advancing RPT and ensuring that evaluation of dosimetry is based on clinical merit rather than logistic constraints. This article examines the current landscape of RPT dosimetry, highlighting key challenges and opportunities from a European perspective and aiming to foster a more factual and constructive discussion on the topic. We discuss the fundamental differences between dosimetry-driven treatment planning and posttherapy absorbed dose verification, emphasizing the latter as a practical entry point for clinical adoption. We underscore the need for harmonized standards, improved imaging resolution, and tailored absorbed dose-effect relationships that reflect the heterogeneity of RPT delivery and the complexity of tumor and organ responses. The paper also addresses regulatory, infrastructural, and resource barriers to RPT dosimetry implementation and highlights ongoing European initiatives to strengthen frameworks, enhance stakeholder collaboration, and integrate absorbed dose biomarkers into authorization processes and clinical decision-making. By rethinking dosimetry and promoting standardized, evidence-based approaches, the field can advance beyond fixed-activity protocols toward truly individualized RPT. However, achieving clinically feasible integration of dosimetry into routine practice requires structured efforts to generate high-quality clinical evidence and improve accessibility. Ultimately, reliable, patient-centered dosimetry has the potential to enhance therapeutic efficacy, manage toxicity more effectively, and support the long-term evolution of RPT as a cornerstone of precision oncology.
引用
- Tran-Gia J, Cicone F, Koole M, et al. Rethinking Dosimetry: A European Perspective. J Nucl Med. 2025. PMID: 40404395. doi:10.2967/jnumed.124.269378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。